Optum Health CEO Says 6%-8% Margin Target Is a 'Multi-Year Journey'
UNH sits 49% above its 52-week low of $255.965 on elevated volume (2.5× avg).
Summary
Optum Health CEO Krista Nelson told investors the division's 6%-8% margin target is a 'multi-year journey,' tempering near-term expectations even as UnitedHealth beat Q3 estimates and raised 2026 guidance to at least $20.50 per share. Optum Health revenue fell 10% year-over-year to $22.9 billion, driven by fewer value-based care patients in markets lacking scale, while Optum Insight rose 3% to $5.5 billion and Optum Rx generated $39.9 billion. The medical care ratio improved to 88.4% from 89.9%, and management said 2027 analyst estimates appear conservative. This follows the Q3 earnings call where executives first outlined 2027 EPS growth expectations, and adds granularity on Optum Health's operational metrics and the timeline for margin recovery. The company also announced AI-powered Medicare Advantage plan recommendations and expects to complete prior authorization reforms by year-end, cutting total prior authorizations by 30%.
At the time of this announcement, UNH was trading at $380.20 on NYSE in the Life Sciences sector, with a market capitalization of approximately $339.1B. The 52-week trading range was $255.97 to $461.62. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Benzinga.